RhumbLine Advisers
RLMD icon

RhumbLine Advisers’s Relmada Therapeutics RLMD Stock Holding History

RhumbLine Advisers’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,125
Closed -$3.38K – 4310
2024
Q2 		$3.38K Sell
1,125
-49
-4% -$177 ﹤0.01% 4140
2024
Q1 		$5.46K Hold
1,174
– – ﹤0.01% 3972
2023
Q4 		$4.86K Hold
1,174
– – ﹤0.01% 3988
2023
Q3 		$3.52K Sell
1,174
-2,274
-66% -$6.75K ﹤0.01% 4037
2023
Q2 		$8.48K Sell
3,448
-34,187
-91% -$94.5K ﹤0.01% 3984
2023
Q1 		$85K Buy
37,635
+1,092
+3% +$3.77K ﹤0.01% 2876
2022
Q4 		$128K Buy
36,543
+280
+0.8% +$2.46K ﹤0.01% 2871
2022
Q3 		$1.34M Buy
36,263
+2,828
+8% +$78.3K ﹤0.01% 1986
2022
Q2 		$635K Buy
33,435
+11,876
+55% +$259K ﹤0.01% 2365
2022
Q1 		$582K Buy
21,559
+5,975
+38% +$124K ﹤0.01% 2354
2021
Q4 		$351K Sell
15,584
-242
-2% -$5.38K ﹤0.01% 2658
2021
Q3 		$415K Buy
15,826
+673
+4% +$18K ﹤0.01% 2630
2021
Q2 		$485K Sell
15,153
-1,240
-8% -$43.1K ﹤0.01% 2579
2021
Q1 		$577K Sell
16,393
-735
-4% -$25.7K ﹤0.01% 2420
2020
Q4 		$549K Buy
17,128
+1,130
+7% +$38.8K ﹤0.01% 2403
2020
Q3 		$602K Sell
15,998
-1,845
-10% -$71.3K ﹤0.01% 2198
2020
Q2 		$798K Buy
+17,843
New +$754K ﹤0.01% 2136

Other funds holding RLMD

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

RhumbLine Advisers's RLMD Position: Q3 2024 in Review

RhumbLine Advisers sold out of Relmada Therapeutics (RLMD) in Q3 2024, closing a stake of 1,125 shares — an estimated $3.38K sold.

RhumbLine Advisers first reported a position in RLMD in Q2 2020 and held it in 17 quarters. The position peaked at $1.34M in Q3 2022. 69 funds tracked by Wall St. Rank hold RLMD as of Q3 2024.

  • RhumbLine Advisers reported no remaining Relmada Therapeutics position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 1,125 Relmada Therapeutics shares in Q3 2024, an estimated $3.38K.
  • RhumbLine Advisers first reported a position in Relmada Therapeutics in Q2 2020 and held it in 17 quarters.
  • RhumbLine Advisers's Relmada Therapeutics position peaked at $1.34M in Q3 2022.
  • 69 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.